Daily GLP-1 tablets are reshaping the race for the obesity market.
Analysts say easier treatment could push the sector toward a $200bn value.
Patients are switching from injections because pills are simpler and cheaper.
Novo Nordisk launched the first oral Wegovy in the US and demand surged immediately.
Many users report steady appetite control without weekly shots.
The tablets also remove the need for refrigeration and needles.
Rising global obesity and limited public coverage are driving private demand.
Health economists believe pills may prove more cost-effective for governments.
However, they currently produce less weight loss than injections.
Competition is intensifying.
Eli Lilly plans to release its own pill, while other firms develop new therapies.
Falling prices and insurance coverage in the US will further expand access.
Injectable drugs will likely remain the choice for severe obesity.
Tablets are expected to attract new patients and move treatment into the mainstream.
